Transforming growth Factor-β in human diabetic nephropathy: Effects of ACE inhibition

Diabetes Care

Volumn 29, Issue 12, 2006, Pages 2670-2675

  Langham, Robyn G ^a,b   Kelly, Darren J ^a   Gow, Renae M ^a   Zhang, Yuan ^a   Cordonnier, Daniel J ^c   Pinel, Nicole ^c   Zaoui, Phillipe ^c   Gilbert, Richard E ^a,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PERINDOPRIL; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; MALE; MIDDLE AGED; PERINDOPRIL; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RNA; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 33845501691     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0911     Document Type: Article

References (30)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
2. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
3. Wolf G: Link between angiotensin II and TGF-β in the kidney. Miner Electrolyte Metab 24:174 -180, 1998
4. Border WA, Yamamoto T, Noble NA: Transforming growth factor-β in diabetic nephropathy. Diabetes Metab Rev 12:309-339, 1996
5. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56:1627-1637, 1999
6. Cordonnier DJ, Pinel N, Barro C, Maynard M, Zaoui P, Halimi S, Hurault de Ligny B, Reznic Y, Simon D, Bilous RW: Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 10:1253-1263, 1999
7. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE: Urinary transforming growth factor- β excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 25:1072-1077, 2002
8. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with longterm renoprotection in insulin- dependent diabetic patients. Am J Kidney Dis 34:818-823, 1999
9. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Path 158:419-429, 2001
10. Tesfamariam B, Brown ML, Cohen RA: Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 87:1643-1648, 1991
11. Haller D, Holt L, Kim SC, Schwabe RF, Sartor RB, Jobin C: Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation. J Biol Chem 278:23851-23860, 2003
12. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM: Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 45:1559-1565, 1997
13. Lehr HA, van der Loos CM, Teeling P, Gown AM: Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J Histochem Cytochem 47:119-126, 1999
14. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155, 1984
15. Bruijn JA, Roos A, de Geus B, de Heer E: Transforming growth factor-beta and the glomerular extracellular matrix in renal pathology. J Lab Clin Med 123:34-47, 1994
16. Shankland SJ, Scholey JW, Ly H, Thai K: Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int 46:430-442, 1994
17. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen UL, Jerums G, Cooper ME: Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 47:414-422, 1998
18. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97:8015- 8020, 2000
19. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
20. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
21. Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 52:1497-1510, 1997
22. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 92:1366-1372, 1993
23. Ziyadeh FN: Role of transforming growth factor beta in diabetic nephropathy. Exp Nephrol 2:137, 1994
24. Yamaguchi Y, Mann DM, Ruoslahti E: Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 346:281-284, 1990
25. O'Connor-McCourt MD, Wakefield LM: Latent transforming growth factor β in serum. J Biol Chem 262:14090-14099, 1987
26. Nakao A, Roijer E, Imamura T, Souchelnytskyi S, Stenman G, Heldin CH, ten Dijke P: Identification of Smad2, a human Mad-related protein in the transforming growth factor beta signaling pathway. J Biol Chem 272:2896-2900, 1997
27. Massague J, Chen YG: Controlling TGF-beta signaling. Genes Dev 14:627-644, 2000
28. Gilbert RE, Wilkinson-Berka JL, Johnson DW, Cox A, Soulis T, Wu LL, Kelly DJ, Jerums G, Pollock CA, Cooper ME: Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats. Kidney Int 54:1052-1062, 1998
29. Langham RG, Egan MK, Dowling JP, Gilbert RE, Thomson NM: Transforming growth factor-β1 and transforming growth factor-β inducible gene H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 72:1826-1829, 2001
30. Shin GT, Kim SJ, Ma KA, Kim HS, Kim D: ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans. Am J Kidney Dis 36:894-902, 2000